Rhythm Reports Two-Year Obesity Drug Data
Phase 3 setmelanotide results show sustained weight reduction in patients with acquired hypothalamic obesity.
Updated on Nov. 17, 2026 in Weight Loss

Rhythm Pharmaceuticals presented two-year Phase 3 setmelanotide results at ObesityWeek 2026 on Monday. Among 125 patients entering the TRANSCEND trial's open-label extension, 81 completed two years of treatment at analysis.
Why it matters
Hypothalamic obesity is a rare, severe form of obesity caused by damage to the hypothalamus, and few treatments address it directly. The data add to evidence on the drug's long-term effects, and the company also presented global diagnostic criteria for the condition at the same meeting.
Of 125 patients entering the open-label extension, 81 completed two years, with 54 on continuous setmelanotide and 27 switching from placebo. Mean BMI change was -18.8% in the continuous arm and -16.5% in the switch arm, while pediatric BMI z-score declines were -1.71 and -1.49, respectively.
The players
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a publicly traded biopharmaceutical company that develops treatments for rare genetic and acquired obesity conditions, and it markets setmelanotide.
Dr. Susan Phillips
Dr. Susan Phillips is a pediatric endocrinologist at the University of California San Diego/Rady Children's Hospital who presented the TRANSCEND extension data.
The details
Dr. Susan Phillips, a pediatric endocrinologist at the University of California San Diego/Rady Children's Hospital, presented the two-year results from the TRANSCEND trial's open-label extension. The safety profile was consistent with earlier acquired hypothalamic obesity trials.
Timeline
March 2026: The FDA approved an expanded indication for Imcivree (setmelanotide) to treat acquired hypothalamic obesity.
November 16, 2026: Rhythm presented the two-year Phase 3 results at ObesityWeek 2026.
Health Landscape
The two-year data follow the FDA's March 2026 approval of Imcivree for acquired hypothalamic obesity, extending the evidence base for a condition with few approved treatments. The results focus on a rare form of obesity rather than the general weight-loss market that dominates the category.
Setmelanotide's safety profile in this extension was consistent with earlier trials, according to the presenting researchers. Patients with acquired hypothalamic obesity and their clinicians may weigh these two-year results when discussing treatment options.
The takeaway
For people with acquired hypothalamic obesity, the two-year data suggest that weight reduction with setmelanotide can be sustained, though the study reports averages and individual outcomes will vary. Anyone considering treatment should discuss the trial results and approved indications with their own clinician.
Further reading
For related coverage, see the Weight Loss section.



